Incyte, Hengrui In ‘Biggest Ever’ China Pharma Out-Licensing Deal
This article was originally published in PharmAsia News
Executive Summary
Incyte has acquired most global rights to an immuno-oncology antibody developed by China's Jiangsu Hengrui, in a deal worth up to nearly $800m plus royalties that will give the US firm a foothold in the PD-1 area and open up new combination therapies.